Press Releases

زار وفد يضم أكثر من عشرين ممثّلًا عن مؤسّسات صينية المملكةَ العربية السعودية لاستكشاف فرص جديدة في السوق الدولية. Leave a reply الرياض، المملكة العربية السعودية, Nov. 28, 2025 (GLOBE NEWSWIRE) — ومؤخرًا، عقد وفد من الشركات الصينية الخاصة، نظّمته منصة خدمات المؤسسات الصينية توچوي لخدمات المؤسسات، مباحثاتٍ تجارية مع وزارة الاستثمار السعودية في العاصمة الرياض. وشارك في اللقاء رئيس مجلس الإدارة والرئيس التنفيذي لـتوچوي لخدمات المؤسسات السيد ڤي جون، إلى جانب أكثر من عشرين ممثلًا عن شركات منها تشيجيانغ جريت وول لمعدات الخلط ولونغتشينغ ساوث إيست (هاينان) للبناء الأخضر. وشملت المناقشات مجالات الاستثمار، والبنية التحتية، والرعاية الصحية، والذكاء الاصطناعي وغيرها. وحضر اللقاء مساعد وكيل الوزارة فهد منصور الهاشم ومسؤولون آخرون، حيث أجرى الجانبان نقاشات عملية تناولت بيئة الاستثمار السعودية والسياسات الصناعية وفرص التعاون بين الشركات الصينية والسعودية. وخلال المداولات، أوضح السيد ڤي جون أن توچوي لخدمات المؤسسات دأبت منذ فترة طويلة على دعم التوسع العالمي للشركات الصينية. ويضم الوفد ممثلين عن قطاعات التصنيع ومواد البناء والتكنولوجيا والتجارة، بهدف تعزيز تكامل الموارد من خلال تعاون عملي بين الشركات الصينية وأسواق الشرق الأوسط. وأضاف السيد ڤي جون أن المملكة العربية السعودية، بوصفها اقتصادًا رئيسيًا في الشرق الأوسط، تعمل بنشاط على دفع مسار التنويع الاقتصادي في إطار رؤية السعودية 2030، مع تركيزها على قطاعات عالية النمو مثل الطاقة الجديدة، وتكنولوجيا المعلومات والاتصالات، والرعاية الصحية، وإنشاء البنية التحتية. وهذه المجالات تتقاطع بصورة وثيقة مع نقاط القوة لدى الشركات الصينية في تطوير التكنولوجيا، ودمج الصناعات، وتوسيع نطاق العمليات. وأكد أن توچوي لخدمات المؤسسات ستوظّف موارد منصّتها لمساعدة الشركات الصينية الخاصة على فهم أفضل للسياسات والبيئة التجارية المحلية، بما يدعم انتقال التعاون من مستوى المنتج إلى نطاق أوسع يشمل سلاسل القيمة الصناعية. وأشار السيد ڤي جون كذلك إلى ضرورة أن تتبنّى الشركات الصينية منظورًا طويل الأمد عند دخولها أسواق الشرق الأوسط، مع التأكيد على أهمية التوطين والالتزام بالأنظمة. وقد بدأت عدة شركات مشاركة بالفعل إجراءات

Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference Leave a reply Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 1:30 p.m. (ET) the same day via webcast. A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at investors.nyxoah.com. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than

ROSEN, A LEADING LAW FIRM, Encourages Stride, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LRN Leave a reply NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Stride, Inc. (NYSE: LRN) between October 22, 2024 and October 28, 2025, both dates inclusive (the “Class Period”), of the important January 12, 2026 lead plaintiff deadline. SO WHAT: If you purchased Stride securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Stride class action, go to https://rosenlegal.com/submit-form/?case_id=30689 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number

ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE Leave a reply NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Skye Bioscience, Inc. class action, go to https://rosenlegal.com/submit-form/?case_id=48064 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities